EntryPoint Capital’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
Other funds holding ANIP
SCM
TCM
GACM
EntryPoint Capital's ANIP Position: Q2 2026 in Review
EntryPoint Capital opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 4,181 shares worth $346K. The stake represents 0.08% of the portfolio and ranks #486 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in ANIP as recently as Q4 2024.
EntryPoint Capital first reported a position in ANIP in Q4 2023 and has held it in 5 quarters since. The position peaked at $444K in Q4 2023. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- EntryPoint Capital held 4,181 shares of ANI Pharmaceuticals worth $346K as of Q2 2026.
- ANI Pharmaceuticals was a new EntryPoint Capital position in Q2 2026.
- ANI Pharmaceuticals made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #486 holding.
- EntryPoint Capital first reported a position in ANI Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
- EntryPoint Capital's ANI Pharmaceuticals position peaked at $444K in Q4 2023.
- 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.